- Home
- QIPT vs PYXS Comparison
QIPT vs PYXS Comparison
Compare QIPT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- PYXS
- Stock Information
- Founded
- QIPT 1993
- PYXS 2018
- Country
- QIPT United States
- PYXS United States
- Employees
- QIPT N/A
- PYXS N/A
- Industry
- QIPT
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- PYXS Health Care
- Exchange
- QIPT Nasdaq
- PYXS Nasdaq
- Market Cap
- QIPT 92.2M
- PYXS 75.0M
- IPO Year
- QIPT N/A
- PYXS 2021
- Fundamental
- Price
- QIPT $2.04
- PYXS $1.23
- Analyst Decision
- QIPT Buy
- PYXS Buy
- Analyst Count
- QIPT 2
- PYXS 4
- Target Price
- QIPT $2.85
- PYXS $8.67
- AVG Volume (30 Days)
- QIPT 296.0K
- PYXS 384.0K
- Earning Date
- QIPT 08-11-2025
- PYXS 08-14-2025
- Dividend Yield
- QIPT N/A
- PYXS N/A
- EPS Growth
- QIPT N/A
- PYXS N/A
- EPS
- QIPT N/A
- PYXS N/A
- Revenue
- QIPT $238,378,000.00
- PYXS $2,820,000.00
- Revenue This Year
- QIPT N/A
- PYXS N/A
- Revenue Next Year
- QIPT $0.72
- PYXS N/A
- P/E Ratio
- QIPT N/A
- PYXS N/A
- Revenue Growth
- QIPT N/A
- PYXS N/A
- 52 Week Low
- QIPT $1.35
- PYXS $0.83
- 52 Week High
- QIPT $3.27
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- QIPT 46.75
- PYXS 60.01
- Support Level
- QIPT $1.90
- PYXS $0.97
- Resistance Level
- QIPT $2.09
- PYXS $1.38
- Average True Range (ATR)
- QIPT 0.17
- PYXS 0.07
- MACD
- QIPT -0.04
- PYXS 0.01
- Stochastic Oscillator
- QIPT 24.78
- PYXS 92.86
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.